What Is Amylin? Benefits, Research & Safety
A pancreatic hormone co-secreted with insulin that regulates glucose and appetite, the basis for the diabetes drug pramlintide.
UK summary: Endogenous pancreatic peptide. Pramlintide (Symlin) is licensed in the US for type 1 / type 2 diabetes; not currently licensed in the UK. Cagrilintide (an analogue) is in late-stage clinical development with Novo Nordisk for obesity.
Quick Facts
Overview
Amylin — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
Endogenous pancreatic peptide. Pramlintide (Symlin) is licensed in the US for type 1 / type 2 diabetes; not currently licensed in the UK. Cagrilintide (an analogue) is in late-stage clinical development with Novo Nordisk for obesity.
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: Pramlintide not widely available; not commonly used in UK practice.
- EU: Pramlintide not approved in EU.
- Notes: Pramlintide is FDA-approved in the US for diabetes. Not approved in UK/EU. Cagrilintide (long-acting analogue) is in development; cagrisema (cagrilintide + semaglutide) is in Phase 3 for obesity with very promising results.
05Approved medical uses
- Pramlintide (SymlinPen) — licensed in the US for type 1 / type 2 diabetes adjunct to insulin (NOT MHRA-licensed in UK).
06Unapproved / promotional claims
- Amylin available for UK private prescription.
- Equivalent to GLP-1s for weight loss.
07Common internet claims
- Marketed by some grey-market vendors as cagrilintide / amylin-pathway products.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Available in the UK as a diabetes treatment” | E | No | High | Pramlintide is not licensed in the UK. UK diabetes pathways use other agents. |
| “Suppresses appetite as effectively as GLP-1” | C | Yes | Moderate | Amylin analogues show appetite-suppression and post-prandial glycaemia effects; head-to-head trials vs GLP-1 are emerging. |
09Safety uncertainty score
Safety profile partly characterised; some signals from observational or preclinical data.
10Known adverse signals
- Hypoglycaemia (when combined with insulin).
- GI side effects (nausea).
- Injection-site reactions.
11Drug-interaction uncertainty
Some interaction data published; check with a prescriber for your specific medicines.
12Anti-doping status
13UK legal position
Pramlintide not widely available; not commonly used in UK practice.
Read the full UK legal guide → Are peptides legal in the UK?
14EU legal position
Pramlintide not approved in EU.
15What this page cannot tell you
- Whether grey-market amylin / cagrilintide products contain the labelled compound.
- Long-term safety of off-label cosmetic-weight use.
16Last reviewed
17Citation quality score
18Research gaps
- Cagrilintide Phase 3 (CagriSema) results awaited.
- Long-term amylin pathway safety beyond licensed pramlintide indication limited.
19Safer alternatives / established care pathways
- Licensed Wegovy / Mounjaro for clinically appropriate weight management.
- NHS diabetes pathway for diabetes management.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Are amylin analogues a UK-licensed option for diabetes or weight management?
- What licensed alternatives should I consider first?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Improved postprandial glucose control
- 2Reduced HbA1c in diabetes (pramlintide)
- 3Weight loss or prevention of weight gain
- 4Reduced glucagon spikes after meals
- 5Satiety enhancement and reduced food intake
- 6Potential for combination obesity therapy (with GLP-1 agonists)
Claim vs Evidence
How popular claims about Amylin stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Available in the UK as a diabetes treatment” | E | No | High | Pramlintide is not licensed in the UK. UK diabetes pathways use other agents. |
| “Suppresses appetite as effectively as GLP-1” | C | Yes | Moderate | Amylin analogues show appetite-suppression and post-prandial glycaemia effects; head-to-head trials vs GLP-1 are emerging. |
Theoretical Dosing & Protocols
| Theoretical Dosage | Pramlintide: 15-120 mcg before meals (FDA approved doses) |
| Frequency | Before major meals (3 times daily) |
| Duration | Ongoing with diabetes management |
| Notes | Pramlintide is approved for use with insulin in type 1 and type 2 diabetes. Must be used alongside appropriate insulin dose reduction to avoid hypoglycemia. Not used as monotherapy. Medical supervision required. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection (pramlintide)
- Longer-acting analogues in development
| Half-Life | Stability |
|---|---|
| Approximately 50 minutes (pramlintide) | Pramlintide stable in solution per manufacturer specifications |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Nausea (common initially, usually improves)
- Headache
- Anorexia/reduced appetite
- Vomiting
- Injection site reactions
Rare Risks & Concerns
- Severe hypoglycemia (especially with inadequate insulin adjustment)
- Gastroparesis (avoid in patients with this condition)
Contraindications
- Gastroparesis
- Hypoglycemia unawareness
- Use requires appropriate insulin dose reduction
- Not for use in place of insulin
UK & EU Regulatory Context
🇬🇧 United Kingdom
Pramlintide not widely available; not commonly used in UK practice.
🇪🇺 European Union
Pramlintide not approved in EU.
Clinical Studies Summary
Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis.
Novel ABTs, such as HiD amycretin, CagriSema and eloralintide, may induce substantial short- to medium-term weight loss but may also increase GI AEs; given sparse, low-certainty data, these findings are preliminary and require confirmation in larger trials. The review protocol summary can be accessed at the PROSPERO website (
Neuropathological links between T2DM and LOAD: systematic review and meta-analysis.
Overall accumulated results highlight the insulin signaling system, vascular markers, inflammation and inflammasome pathways, amylin interactions, and glycosylation mechanisms. The protocol was registered with PROSPERO (ID: CRD42023440535).
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
Our findings show cardiovascular safety across all GLP-1 receptor agonist cardiovascular outcome trials and suggest that drugs in this class can reduce three-point major adverse cardiovascular events, cardiovascular mortality, and all-cause mortality risk, albeit to varying degrees for individual drugs, without significant safety concerns.
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial.
In people with overweight or obesity, amycretin appeared safe and tolerable. Results from this first-in-human, phase 1 study support further investigation of the weight loss properties of amycretin.
Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept.
Once-weekly dosing with eloralintide, an AMY1R-selective agonist, may offer a promising new therapeutic with favorable gastrointestinal tolerability for the treatment of obesity.
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.
In people with overweight or obesity, once-weekly subcutaneous amycretin up to 60 mg had a safety and tolerability profile consistent with GLP-1 and amylin agonists. Although a high frequency of gastrointestinal events was reported, rates were similar to those seen in early-phase studies of these molecules. These results support further investigation into the weight loss properties of amycretin.
Registered Trials & Regulatory Status
6 of 6 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.
Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)
Status: Recruiting · 100 participants · Novo Nordisk A/S
Conditions: Obesity
Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans
Status: Recruiting · 18 participants · University Hospital, Gentofte, Copenhagen
Conditions: Obesity & Overweight
A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese
Status: Recruiting · 100 participants · Novo Nordisk A/S
Conditions: Overweight, Obese
Hypersensitivity to Amylin in Post-Traumatic Headache
Status: Not Yet Recruiting · 21 participants · Danish Headache Center
Conditions: Headache Disorders, Secondary, Brain Diseases, Headache Disorders
Amylin-Induced Migraine Attacks Without Aura
Status: Not Yet Recruiting · 21 participants · Danish Headache Center
Conditions: Headache Disorders, Primary, Headache Disorders, Brain Diseases
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism
Status: Recruiting · 144 participants · Novo Nordisk A/S
Conditions: Obesity
"Longitudinal Analysis of Amylin Levels in Migraine Patients Undergoing an Anti- CGRP/CGRPr Treatment"
Status: Not Yet Recruiting · 216 participants · Fundación Marques de Valdecilla
Conditions: High Frequency Episodic Migraine and Chronic Migraine
The Role of Amylin in Bone Metabolism
Status: Unknown · 20 participants · Filip Krag Knop
Conditions: Bone Diseases, Metabolic, Type 1 Diabetes
Amylin and CGRP Head to Head Provocation in Migraine Without Aura Patients
Status: Completed · 36 participants · Danish Headache Center
Conditions: Migraine Without Aura
A Causative Role for Amylin in Diabetic Peripheral Neuropathy
Status: Recruiting · 40 participants · Zabeen Mahuwala, MD
Conditions: Type2 Diabetes, Peripheral Neuropathy
Serum Preptin and Amylin Levels in Polycystic Ovary Syndrome Patients
Status: Completed · 80 participants · Recep Tayyip Erdogan University Training and Research Hospital
Conditions: Polycystic Ovary Syndrome
Myocardial Protection of Exenatide in AMI
Status: Completed · 127 participants · Kyunghee University Medical Center
Conditions: Myocardial Infarction
Adverse event reports (FDA FAERS)
Not applicable: no licensed product contains this peptide, so it is not reported through FAERS. This is an absence of surveillance, not evidence of safety.
Source: ClinicalTrials.gov and openFDA. Updated automatically.
Looking for Amylin?
Source research-grade Amylin from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about Amylin
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Are amylin analogues a UK-licensed option for diabetes or weight management?
- What licensed alternatives should I consider first?
UK regulatory & safety context
Related Peptides
Semaglutide
A GLP-1 receptor agonist approved for type 2 diabetes and obesity treatment, representing one of the most significant advances in weight management pharmacotherapy.
Learn moreLiraglutide
An earlier GLP-1 receptor agonist approved for diabetes and weight management, offering once-daily dosing with proven efficacy and safety.
Learn moreGLP-1
A naturally occurring gut hormone that regulates glucose metabolism and appetite, serving as the basis for major obesity and diabetes medications.
Learn moreGhrelin
The 'hunger hormone' that stimulates appetite and growth hormone release, with important roles in metabolism and energy balance.
Learn more